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Abstract
Background: The impact of clinical and sociodemographic factors on fatigue remains unknown among patients
with substance use disorders (SUD). This study aims to evaluate fatigue among patients with SUD using a nine-item
fatigue severity scale (FSS-9) and identify the impact that clinical and sociodemographic factors – such as injecting
substance use, chronic infectious diseases, liver fibrosis, opioid agonist therapy (OAT), debt difficulties, and housing
situation – have on fatigue.
Methods: We used data from a cohort of patients with SUD in Norway with annual health assessments surveying
FSS-9 and some clinical and sociodemographic factors. A total of 915 FSS-9 measurements were collected from 654
patients during the period 2016–2020. We defined baseline as the first annual health assessment when the health
assessments were listed chronologically. Time was defined as years from baseline. We used a linear mixed model to
analyse whether the clinical and sociodemographic factors affected the FSS-9 sum score, presented with beta
coefficients (β) with 95% confidence intervals (CI).
Results: The mean sum score of the FSS-9 was 43 (standard deviation: 16) at baseline. Females compared with
males (adjusted mean difference of FSS-9 sum score: 4.1, 95% CI: 1.3–7.0), having debt difficulties compared with
having no debt difficulties (2.9;0.4–5.3), and frequent use of benzodiazepines (5.7;3.0–8.4) or amphetamines (-5.0;-
8.0– -2.0) compared to less frequent or no use of these substances changed the FSS-9 baseline sum score. The
other clinical and sociodemographic factors did not predict any clinically relevant change in the FSS-9 sum score
from baseline to the following health assessments.
Conclusion: Patients with SUD suffer from high levels of fatigue. Female patients, patients with debt difficulties,
and those with extensive use of benzodiazepines are at particular risk of being fatigued. This should be taken into
consideration when planning health services.
Keywords: Substance-related disorders, Fatigue, Fatigue severity scale, Quality of life, Comorbidities, Illicit drugs,
Viral human hepatitis, HIV, Kidney disease
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Background
Patients with Substance Use Disorders (SUD) suffer
from a broad range of health-related difficulties that may
contribute to fatigue [1–3]. Fatigue presents itself as a
persistent and overwhelming feeling of exhaustion and
loss of energy. The condition is mainly associated with
chronic diseases and may mitigate treatment adherence
and exacerbate comorbid disorders [4, 5]. In SUD popu-
lations, a myriad of external factors can interact with fa-
tigue and affect these patients’ general well-being [6–8].
Injecting substance use, internal organ dysfunctions
(predominantly kidney and liver diseases), mental disor-
ders, as well as low income, unemployment, and home-
lessness are some of the external factors that interact
with fatigue. Despite this, relatively little attention has
been paid to the extent of fatigue and how much various
external factors influence fatigue among patients with
SUD. Therefore, understanding the key factors affecting
fatigue is essential to improve treatment outcomes and
adherence in this population.
Fatigue is associated with several sociodemographic
and clinical factors. Among patients with the Hepatitis C
Virus (HCV) infection, 50–70% have reported fatigue
[9–11], while 33–88% of those with the Human Im-
munodeficiency Virus (HIV) infection have presented
the same symptom [12]. A more uncertain prevalence of
fatigue is seen among patients with the Hepatitis B Virus
(HBV) [13, 14]. In addition, females, patients with lower
educational levels, and those with opioid use disorders
undergoing Opioid Agonist Therapy (OAT) with metha-
done or buprenorphine generally have a greater risk of
fatigue [15, 16]. Disentangling the effects of the potential
factors influencing fatigue in patients with SUD is essen-
tial for individualised treatment and developing clinical
guidelines.
Fatigue is a subjective concept, and various definitions
and instruments are used in the literature to capture it,
which makes interpretations more complicated [17–19].
The nine-item fatigue severity scale (FSS-9) is a well-
known questionnaire used to quantify fatigue treatment
effects. It shows excellent validity and reliability across
various chronic neurological and infectious diseases,
such as multiple sclerosis [17], HCV infection [20],
stroke [5], and Parkinson’s disease [21]. The fact that
FSS-9 shows a high consistency across various chronic
diseases makes it particularly suitable to estimate fatigue
among patients suffering from SUD with complex and
challenging comorbidities.
Thus, this prospective cohort study aims to investigate
fatigue using the nine-item Fatigue severity scale (FSS-9)
among patients with substance use disorders (SUDs) and
predict the impact of sociodemographic and clinical fac-
tors on FSS-9, including educational level, housing situ-
ation, debt difficulties, chronic infectious diseases,
injecting substance use, substance use, liver fibrosis, and
kidney disease. Moreover, we estimate:
1) using annual health assessments, the FSS-9 sum
score and whether and to what extent the sociode-
mographic and clinical factors impact this score;
2) the impact of sociodemographic and clinical factors
on changes in the FSS-9 sum score from the first
health assessment to the following annual health
assessments;
3) for two separate subgroups – patients receiving
methadone as opioid agonist therapy (OAT) and
those receiving buprenorphine as OAT – the FSS-9
sum score, whether and to what extent the sociode-
mographic and clinical factors affect the FSS-9 sum
score at baseline, and any changes in the FSS-9 sum
score from the first health assessment to the follow-
ing annual health assessments.
Methods
Data source
We used data from a cohort nested to the INTRO-HCV
trial on patients with SUD in Bergen and Stavanger,
Norway [22]. We collected data from May 2016 to Janu-
ary 2020, and recruited patients on OAT from out-
patient clinics in Bergen and Stavanger, as well as
patients with various SUDs receiving primary healthcare
from the municipality clinics in the city of Bergen.
Data collections
All included patients were assessed yearly with a health
assessment, including FSS-9 measurements, sociodemo-
graphic data, and current substance use. Additionally,
blood samples and liver fibrosis measurements using
transient elastography were conducted. We collected all
data in a health register using electronic data collection
software (Checkware®) under research nurses’ supervi-
sion. All the clinical data, including information regard-
ing OAT, OAT medication, substance use, and possible
comorbid clinical conditions, were collected from the
electronic medical record.
Study sample
We included 915 FSS-9 measurements from 654 patients
in the study period. In total, 225 had follow-up data and
conducted the health assessment, including the FSS-9
questionnaire, twice (n = 188) or thrice (n = 37), provid-
ing 487 repeated measurements. The median time inter-
val between the baseline health assessments, and any
subsequent assessments in the same patients, including
FSS-9 measurements, was 11 months (interquartile range
(IQR): 9–14) (Additional file 1).
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Measuring fatigue
We measured fatigue during the last week using FSS-9,
including items considering: mental and physical func-
tioning, motivation, carrying out duties, and interference
with work, family, or social life. An FSS-9 measurement
was completed when all nine items in the questionnaires
were entirely conducted during an annual health assess-
ment. The FSS-9 items were answered on a Likert scale
– ranging from 1 (no fatigue) to 7 (worst fatigue) – that
demonstrates the fatigue level. A high score of FSS-9
items notes a high level of fatigue, while a mean FSS-9
item score greater than 4.0 revealed severe fatigue. The
data collection software only allowed valid responses to
each question and prompted empty questions before
submission to minimise missing data. The FSS-9 was
also translated and back-translated from the US-English
version into Norwegian by qualified native Norwegian-
speaking translators (Additional file 2) [23].
Measuring liver stiffness and assessing blood samples
We assessed liver stiffness using transient elastography
(Fibroscan®) to reveal liver fibrosis and cirrhosis. The
elastography was reported as a median score of 10 mea-
surements conducted by research nurses. A liver stiff-
ness above 10 kilopascals (kPa) was defined as liver
fibrosis, while a value above 12.5 kPa indicated liver cir-
rhosis [24]. We also collected blood samples, including
hemoglobin, thrombocytes, C - reactive protein, aspar-
tate aminotransferase, estimated glomerular filtration
rate, hepatitis B surface antigen, HIV antigen/antibodies,
HCV antibodies, and HCV polymerase chain reaction
(HCV PCR) during the annual health assessment. Liver
stiffness was estimated by calculating the AST to platelet
ratio index (APRI) score and using transient elastogra-
phy (Fibroscan®) (Additional file 3). Moreover, the
hematological and biochemical samples were analysed to
detect anemia (Hemoglobin), infection or inflammation
(C – reactive protein), kidney disease (estimated glom-
erular filtration rate), liver disease (APRI), or chronic in-
fectious diseases (HIV, HCV, and HBV), which could
affect the FSS-9 score. Both elastography and blood sam-
ples were examined annually and simultaneously when
conducting the annual health assessments. We analysed
the blood samples at the Department of Laboratory
Medicine, Haukeland University Hospital, Bergen,
Norway, and at the Department of Medical Biochemistry
and Microbiology, Stavanger University Hospital, Sta-
vanger, Norway (accredited by ISO-standard 15,189).
Definition of study variables, including sociodemographic
and clinical factors
We defined baseline for patients as the first annual
health assessment that included an FSS-9 measurement
when we listed the health assessments chronologically.
We dealt with each FSS-9 measurement as a sum score
by summarising the value (one to seven) from each item
and as a mean score calculated by dividing the sum
score by nine (nine items). We defined being on OAT
according to whether patients received buprenorphine
or methadone (OAT opioids) at baseline. Further, in ac-
cordance with the World Health Organization’s stan-
dards, we calculated the daily dose of received OAT
opioids as a ratio between the received dose per day di-
vided by the expected mean dose of OAT opioids
(buprenorphine 18mg, buprenorphine-naloxone 18/4.5
mg or methadone 90 mg) [25]. We categorised educa-
tional level into five groups: ‘not completed primary
school,’ ‘completed primary school (nine years),’ ‘com-
pleted high school (12 years),’ ‘three or fewer years of
college or university’ or ‘more than three years of college
or university.’ Patients’ housing situations in the 30 days
prior to the FSS-9 measurement were classified into two
groups: “stable” and “unstable.” The latter category in-
volved patients who had lived on the street, in a home-
less shelter, or with family and friends during the past
30 days. Others who had a more permanent residence
were classified as having a stable housing situation. Debt
difficulties were defined as striving with paying off legal
or illegal debt due to a constrained private economy. We
set ‘injecting substance use’ as having injected at any
time during the past 12 months, whereas frequent sub-
stance use was categorised as consuming at least one of
the substance groups, including ‘benzodiazepines or z-
hypnotics,’ ‘cannabis,’ ‘stimulants (amphetamines or co-
caine),’ ‘alcohol,’ and ‘heroin or other illicit opioids’,
more than weekly during the 12 months prior to a health
assessment. Patients who did not use substances or used
them less than weekly during the past 12 months were
categorised as having ‘no frequent use of substance’.
Having chronic infectious diseases was defined as detect-
ing HCV PCR (HCV), hepatitis B surface antigen (HBV),
or HIV antigen/antibodies (HIV) in the blood samples.
For HCV PCR, we used the Helmert contrast in order to
classify patients into two groups – transmitted and non-
transmitted – and further into two subgroups: whether
patients have a low viral load (< 800,000 IU/ml) or high
viral load (≥ 800,000 IU/ml). By this two-fold division,
we investigated whether the level of viral HCV load was
associated with changes in the fatigue level.
Statistical analyses
We used Stata/SE 16.0 (StataCorp, TX, USA) for de-
scriptive analysis and IBM SPSS version 26.0 for
expectation-maximisation imputation and linear mixed
model analyses. The threshold for statistical significance
was set to P < 0.05 for all analyses unless otherwise
stated. In all analyses, we defined time as years from
baseline.
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We dealt with any missing values concerning sociode-
mographic and clinical factors – such as educational
level, housing situation, debt difficulties, receiving OAT,
OAT opioid dose ratio, injecting substance use, sub-
stance use, and the results of defined blood samples and
transient elastography – as ‘missing at random’ when
running expectation-maximisation imputation. We iden-
tified missing values in 2.6% in these factors and all were
replaced with estimated values by imputation.
The FSS-9 sum score at baseline was calculated by
summarising the nine items’ points. Linear mixed model
analyses were used to investigate whether the sociode-
mographic and clinical factors affected the FSS-9 sum
score and to what extent they impacted any changes in
the score from baseline to following the health assess-
ments. First, the factor variables were analysed separately
as outcome variables as a function of the time (time
from baseline). We did not identify substantial signifi-
cant changes in the sociodemographic and clinical fac-
tors between the annual health assessments (data not
shown). Thus, baseline levels were used as stable predic-
tors in the prediction of the level and changes in FSS-9.
We specified the linear mixed models as a random inter-
cept fixed slope regression model. The estimator was set
to Restricted Maximum Likelihood. To explore whether
predictors predicted changes in outcome, the interac-
tions between these factors and time were added to the
model. The full information maximum likelihood en-
sured that all available FSS-9 sum score measurements
were used. Additionally, we presented sub-group ana-
lyses for OAT patients using methadone or buprenor-
phine, respectively. For these analyses, we added the
OAT opioid ratio as a predictor. The potential correla-
tions between sociodemographic and clinical factors and
fatigue are presented in Additional file 4. We performed
a sensitivity analysis by adding Bonferroni corrected p-
values to adjust for Type I errors in all analyses.
Ethics approval and consent to participate
The study is reviewed and approved by the Regional
Ethical Committee for Health Research West, Norway
(REK Vest 2017/51). Each patient provided written in-
formed consent prior to enrolling in the study.
Results
Patients characteristics at baseline
Seventy-one percent of patients were male, and the mean
age was 43 years (standard deviation (SD): 11 years) at base-
line (Table 1). Six percent had not completed primary school,
or 44% had primary school as their highest educational level.
82% received OAT, of which 60% received buprenorphine or
buprenorphine-naloxone as an OAT opioid. Further, 13%
had an unstable housing situation in the last 30 days leading
up to the FSS-9 measurement. 73% had used at least one
substance weekly during the past 12months.
FSS-9 sum scores at baseline
The mean sum score for the FSS-9 was 43 (SD: 16),
representing a mean score for the FSS-9 items of 4.8
(2.6) (Table 2). A total of 69% of patients had severe fa-
tigue. The mean FSS-9 sum score was slightly left-
skewed (skewness: − 0.7) and tended towards a flattened
distribution (kurtosis: 2.4).
The mean scores for the FSS-9 were 43 (SD: 16) for pa-
tients receiving methadone and 43 (17) for those using
buprenorphine (Additional file 5), corresponding to a mean
score for the FSS-9 items of 4.8 (1.8) for patients receiving
methadone and 4.7 (1.9) for those using buprenorphine. Se-
vere fatigue was identified in 77% of patients receiving
methadone and 67% of those using buprenorphine. In these
two sub-groups, the FSS-9 sum scores were slightly left-
skewed (skewness: − 1.0 (methadone group), − 0.6 (bupre-
norphine group)) and flattened distributed (kurtosis: 3.0
(methadone group), 2.2 (buprenorphine group)).
The sociodemographic and clinical factors’ impact on the
FSS-9 sum score at baseline and the factors’ influence on
changes in the FSS-9 sum score from baseline to the
following annual health assessments
At baseline, we found that the FSS-9 sum score was higher
for females than males (adjusted mean FSS-9 sum score dif-
ference: 4.1, CI 1.3;7.0, p= 0.005), for patients with debt diffi-
culties compared with those without debt difficulties (2.9, CI
0.4;5.3, p= 0.022), and for patients with frequent benzodi-
azepine use compared with those with less frequent or no
use (5.7, CI 3.0;8.4, p < 0.001) (Table 3). In contrast, the FSS-
9 sum score was lower for patients with frequent stimulant
use than those with less frequent or no use (− 5.0, CI -8.0;-
2.0, p= 0.001). Moreover, we saw a small non-clinical signifi-
cant reduction of the FSS-9 sum score from baseline to the
following annual health assessments for patients with fre-
quent benzodiazepine use compared to those with less fre-
quent or no use (− 4.4, CI -8.2;-0.7, p= 0.021) and for
patients having significant liver fibrosis or cirrhosis measured
by transient elastography compared with those with non-
significant fibrosis or normal liver stiffness (− 5.5, CI -9.9;-1.0,
p= 0.016). With Bonferroni corrected p-values, we only
found that patients with frequent benzodiazepine or stimu-
lant use compared with those with less frequent or no use of
these substances changed the fatigue levels at baseline.
The sociodemographic and clinical factors’ impact on
changes in the FSS-9 sum score from baseline to the
following annual health assessments among patients on
OAT
Among patients receiving methadone as an OAT opioid,
we found that the FSS-9 sum score was higher for
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Age (years), n (%)
18–29 81 (12) 23 (10)
30–39 185 (28) 63 (28)
40–49 205 (31) 75 (33)
50–59 148 (23) 53 (24)
≥ 60 35 (5) 11 (5)
Mean (SD) 43 (11) 44 (10)
Gender, n (%)
Male 461 (71) 170 (76)
Female 193 (29) 55 (24)
Highest educational level, n (%)
Not completed primary school 40 (6) 15 (7)
Completed primary school (9 years) 286 (44) 105 (47)
Completed high school (12 years) 259 (40) 81 (36)
≤ 3 years of college or university 57 (9) 20 (9)
> 3 years of college or university 12 (2) <5 (2)
Receiving opioid agonist therapy, n (%) 537 (82) 205 (91)
OAT opioid (%)
Methadone 209 (39) 96 (43)
Buprenorphine/Buprenorphine-naloxone 321 (60) 107 (48)
OAT opioid dose ratio (median (IQR))a 0.9 (0.8–1.1) 1.0 (0.9–1.1)
Housing situation the past 30 days, n (%)
Stableb 569 (87) 203 (90)
Unstablec 85 (13) 22 (10)
Injected substances the past 12 months, n (%) 338 (56) 116 (52)
Frequent substance use the past 12 months, n (%)d
Alcohol 154 (26) 56 (25)
Benzodiazepines 238 (39) 87 (39)
Cannabis 313 (52) 124 (55)
Opioids 97 (16) 27 (12)
Stimulants (amphetamines and cocaine) 176 (29) 60 (27)
Chronic infectious diseases, n (%)
Hepatitis C virus infection 315 (48) 184 (82)
Low virulent (< 800,000 IE/ml) 168 (25) 92 (41)
High virulent (≥ 800,000 IE/ml) 147 (22) 92 (41)
Hepatitis B virus infection 5 (0) < 5 (< 1)
Human immunodeficiency virus < 5 (< 1) < 5 (< 1)
Hematological and biochemical samples, median (IQR)
Hemoglobin (g/dl) 14 (13–15) 14 (13–15)
Estimated glomerulus filtration rate (ml/min/1.73 m2) 104 (89–122) 105 (91–124)
C-reactive protein (mg/L) 4 (1–9) 3 (1–8)
Aspartate transaminase (U/L) 31 (23–50) 40 (30–65)
Vold et al. Substance Abuse Treatment, Prevention, and Policy           (2020) 15:93 Page 5 of 11
females than males (7.3, CI 2.5;12.2, p = 0.003), for pa-
tients having debt difficulties compared with those not
having debt difficulties (4.9, CI 0.7;9.1, p = 0.023), for pa-
tients having frequent benzodiazepine use compared
with those having less frequent or no use (6.0, CI 1.6;
10.5, p = 0.008), and for patients with a high HCV viral
load compared with those with a low HCV viral load
(31.5, CI 1.5;61.5, p = 0.040) at baseline (Additional file 6).
Among patients receiving buprenorphine as an OAT
opioid, we found that patients with frequent alcohol use
had higher the FSS-9 sum score (4.8, CI 0.2;9.3, p =
0.039), while patients with frequent stimulant use had
lower the FSS-9 score (− 5.0, CI -9.9;-0.1, p = 0.047)
compared with patients with less frequent or no use of
these substances at baseline (Additional file 7). For both
subgroups, no sociodemographic and clinical factors
were clinically associated with substantial changes in the
FSS-9 sum score from baseline to the following annual
health assessments. With Bonferroni corrected p-values,
we did not identify any predictors that changed the fa-
tigue score at baseline and between the annual health
assessments.
Discussion
This study showed that 69% of SUD patients had severe
fatigue symptoms. The sociodemographic and clinical
factors that substantially contributed to higher fatigue
scores at baseline were females compared with males
(four points), frequent benzodiazepine use compared
with less frequent or no use (six points), and debt diffi-
culties compared with no debt difficulties (three points).
However, the fatigue score was five points lower for pa-
tients with frequent stimulant use than those with less
frequent or no use. For patients using buprenorphine as
an OAT opioid, we found five points lower fatigue score
for patients with frequent stimulant use and five points
higher fatigue score for patients with frequent alcohol








Liver stiffness, median (IQR)
Transient elastography (kPa) 5 (4–7) 6 (5–8)
Aspartate transaminase to platelets ratio index 0.3 (0.2–0.6) 0.4 (0.3–0.8)
The table displays the sociodemographic and clinical characteristics for all included patients, and for patients with two or more health assessments, including FSS-
9 measurements at baseline
FSS-9 nine-item fatigue severity scale (Likert scale), IQR interquartile range, kPa kilopascal, OAT opioid agonist therapy, SD standard deviation
aOAT opioid ratio is a ratio between the received dose of OAT opioids per day and the expected median daily dose (18 mg buprenorphine, 18/4.5 mg
buprenorphine-naloxone or 90mg methadone). A ratio on 1.0 indicates that patients received the expected daily dose; bA stable housing situation was defined as
having owned or rented housing situation or being imprisoned; cUnstable housing situation was defined as living in a homeless shelter, with family or friends, or
on the street; dFrequent substance use was defined as using substance at least weekly during the past 12 months
Table 2 Mean (Standard deviation (SD)) item scores for single items on FSS-9 at baseline and follow-up
Baseline (N = 654) Follow-up (N = 225)
FSS-9
I1: My motivation is lower when I am fatigued 5.4 (2.0) 5.6 (2.0)
I2: Exercise brings on my fatigue 4.7 (2.1) 5.0 (2.0)
I3: I am easily fatigued 4.5 (2.1) 4.8 (2.1)
I4: Fatigue interferes with my physical functioning 4.9 (2.1) 5.1 (2.0)
I5: Fatigue causes frequent problems for me 4.4 (2.2) 4.5 (2.2)
I6: My fatigue prevents sustained physical functioning 4.6 (2.2) 4.4 (2.2)
I7: Fatigue interferes with carrying out certain duties and responsibilities 5.0 (2.1) 5.0 (2.1)
I8: Fatigue is among my three most disabling symptoms 4.6 (2.3) 4.8 (2.3)
I9: Fatigue interferes with my work, family, or social life 4.9 (2.2) 4.6 (2.3)
Mean score of all items 4.8 (1.8) 4.9 (1.7)
Sum score of all items 43.2 (15.9) 43.8 (15.2)
Follow-up: FSS-9 score on the last health assessment during the study period among patients with two or more annual health assessments; FSS-9 nine-item
fatigue severity scale (Likert scale ranging from 1 (no fatigue) to 7 (worst fatigue)), I Item, SD standard deviation
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use compared with those with less frequent or no use of
these substances at baseline. For patients receiving
methadone as an OAT opioid, the fatigue score was
higher for females than males (seven points), for patients
with frequent benzodiazepine use compared with those
with less frequent or no use (six points), for patients
with debt difficulties compared with those without diffi-
culties with debt (five points), and for patients with a
high versus a low viral load of HCV (32 points) at base-
line. The latter finding suggesting an extreme difference
between a high and a low viral load of HCV was surpris-
ing. Other studies assessing HCV viral load and correl-
ation based on clinical and histological features have
also not found HCV viral load to impact other related
outcomes [26–28]. This finding is likely related to ran-
dom variability within the data, and it should be inter-
preted with caution. Moreover, no sociodemographic
and clinical factors were associated with clinically signifi-
cant changes in the fatigue score from baseline to the
following health assessments.
Table 3 Linear mixed model of fatigue (FSS-9) adjusted for sociodemographic and clinical factors (N = 654)
Fixed effects
Effect estimate Time trend (per year)
Estimate (95% CI) p-value Slope (95% CI) p-value
FSS-9 sum score 42 (26–58) < .001 3.6 (−23.5–30.7) 0.792
Female 4.1 (1.3–7.0) 0.005 −0.3 (−4.5–3.8) 0.877
Age per 10 years1) 0.2 (−1.0–1.4) 0.755 −0.2 (− 2.1–1.7) 0.844
Educational level − 1.1 (− 2.6–0.3) 0.132 −0.3 (− 2.3–1.7) 0.754
Unstable housing situation 0.0 (−3.7–3.7) 0.992 2.6 (− 3.6–8.8) 0.408
Debt difficulties 2.9 (0.4–5.3) 0.022 −0.2 (− 3.8–3.3) 0.898
Injecting substance use −0.1 (− 2.9–2.7) 0.944 −0.7 (− 4.6–3.3) 0.740
Frequent use of substances
Benzodiazepines 5.7 (3.0–8.4) < .001a −4.4 (−8.2 – − 0.7) 0.021
Alcohol 1.8 (−1.1–4.6) 0.221 0.6 (−3.5–4.7) 0.776
Cannabis 1.2 (− 1.4–3.8) 0.356 1.8 (− 1.7–5.3) 0.309
Opioids 3.3 (− 0.3–6.9) 0.069 −4.6 (− 10.8–1.7) 0.149
Stimulants2) − 5.0 (− 8.0– − 2.0) 0.001 a 2.1 (− 2.1–6.3) 0.327
Chronic infectious diseases
Hepatitis B virus infection 3.3 (− 10.4–16.9) 0.638 −2.6 (− 16.8–11.5) 0.715
Hepatitis C virus infection
- Detected 3.0 (− 5.4–11.4) 0.484 0.7 (− 18.7–20.1) 0.941
- Low vs. high viral load − 0.4 (− 10.3–10.9) 0.948 − 7.0 (− 17.1–3.0) 0.169
HIV − 0.1 (− 15.3–15.5) 0.994 13.0 (− 6.8–32.7) 0.197
Liver stiffness
Transient elastography per 10 kPa 1.2 (−1.6–4.0) 0.391 −5.5 (− 9.9 – − 1.0) 0.016
APRI score per 1 unit 0.5 (− 0.6–1.5) 0.378 1.4 (− 0.9–3.6) 0.230
Hematologic and biochemical blood samples (continuous variables)
Hemoglobin per 1 unit (g/dL) −0.3 (− 1.1–0.6) 0.513 0.3 (− 0.9–1.5) 0.622
eGFR per 30 units (ml/min/1.73m2) 0.0 (− 2.0–0.9) 0.453 0.0 (− 2.0–1.9) 0.973
CRP per 10 units (ml/L) −0.1 (− 0.6–0.7) 0.848 0.0 (− 0.1–0.2) 0.682
The table displays a linear mixed model analysis (Restricted Maximum Likelihood regression) evaluating sociodemographic and clinical factors’ (predictors)
changes in the FSS-9 sum score at baseline and the predictors’ influence on changes in the FSS-9 sum score (time trend) per year from baseline. The predictors’
effect estimates and time trends estimate adjusted mean differences in the FSS-9 sum score
APRI aspartate transaminase to platelet ratio index, CI confidence interval, CRP C-reactive protein, FSS-9 nine-item fatigue severity scale, eGFR estimated glomerular
filtration rate, HIV human immunodeficiency virus, kPa Kilopascal, OAT opioid agonist therapy
1) Age per 10 years was centred according to mean age (43 years) in the study sample at baseline. 2) Includes amphetamine or cocaine use. The educational level:
highest level of education was coded 0–4 with 4 as the highest educational level. Unstable housing situation: living on the street, homeless shelter, or with family
and friends at any time during the past 30 days prior to the health assessment. Debt difficulties: struggling with repaying current illegal and legal debt. Injecting
substance use: Having injected substance during the past 12 months prior to the health assessment. Frequent use of substances: at least weekly during the past
12 months prior to the health assessment. Viral load of HCV: From − 0.5 to 0.5, where the range ≥ − 0.5 to < 0 represents the low viral load (HCV PCR < 800,000 IE/
ml), and the range ≤ 0.5 to > 0 identifies the high viral load (HCV PCR ≥ 800,000 IE/ml). Zero (0) defined patients without HCV infection
a) Statistically significant results when using Bonferroni corrected p-values (αaltered = 0.05 / 41 = 0.0012)
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In the present study, patients with SUD had a mean
fatigue score (4.8) comparable to some of the most se-
vere chronic diseases. In recent studies, patients infected
with HIV or HCV, or those co-infected with both of
them, have a mean FSS-9 score that ranged from 3.3 to
4.5 [10, 29, 30]. Patients with myasthenia gravis have re-
ported a comparable fatigue score of 4.7 [31], and simi-
larly, so have patients who have suffered from a stroke
at least 6 months after the stroke onset (4.8) [32]. One
can assume that a high prevalence of underlying mental
disorders, extensive polysubstance use, and lower social
status could have attributed to the high level of fatigue
in the SUD population.
We found that females were weakly more fatigued
than males. For both genders, patients with frequent
use of benzodiazepines were weakly more fatigued
than those with less frequent or no use. Recent stud-
ies evaluating fatigue in the general population and
patients with chronic disorders have demonstrated
similar gender differences in fatigue levels [15, 23, 31,
33]. Gender inequalities regarding household responsi-
bilities and caring for the family have generally been
highlighted as explanations for females’ fatigue levels
[34]. Additionally, females with SUD may be worse
off than males in many domains. They may have less
financial resources, experience more physical trauma
caused by exchanging sex for drugs and money, and
face more stigma related to family failures [34]. More-
over, in the general population and among patients
with SUDs, females are more likely to use benzodiaz-
epines than males, with a similar tendency found in
different countries [2, 35–38]. Females’ higher preva-
lence of anxiety disorders, sleeping disorders and the
fact that they are more likely to seek medical care
may contribute to more prescriptions of hypnotics
and anxiolytics, such as benzodiazepines and z-
hypnotics [39–41]. One can believe that these med-
ical, psychological, and social challenges may overall
explain the gender gap concerning a higher fatigue
level among females in the SUD population.
Our findings revealed that patients with frequent use
of benzodiazepines were weakly more fatigued than
those with less frequent or no use. Among patients with
frequent use of stimulants, we found that they were less
fatigued than those with less frequent or no use. These
group differences were overall small. In the general
population, previous studies assessing the effect of
benzodiazepine use have suggested that patients using
benzodiazepines have a lower quality of life, self-
reported physical health, and more disability than those
not using benzodiazepines [42, 43]. This is parallel with
the higher fatigue levels shown in the present study. Fur-
thermore, using stimulants, particularly illicit amphet-
amines, is generally associated with poor mental health
and stimulant withdrawal symptoms in the SUD popula-
tions [44, 45]. A temporary sense of better self-perceived
mental health and fewer withdrawal symptoms may arise
when consuming stimulant substances, which contrib-
utes to a temporary reduction of fatigue compared to
the experience without stimulants. However, our trend
analyses indicate that the fatigue levels remained stable
over time when the frequent use of stimulants is
persistent.
The present study showed no clear associations be-
tween fatigue and chronic infectious diseases or kidney
disease. For patients with HBV, HIV or end-stage kidney
disease, the low prevalence of HBV and HIV and a mean
renal function within the normal range could explain
why no associations with fatigue were detected. Further-
more, we are surprised that SUD patients with HCV in-
fections did not demonstrate a higher fatigue level
compared to patients with SUD without HCV infection,
considering that the prevalence of fatigue is up to 70%
in populations with HCV [9–11], which is considerably
higher than in general population [23]. However, the
large extent of polysubstance use in the present popula-
tion (75%) could have temporarily displaced the HCV in-
fection’s change on fatigue.
We found that 77% of patients using methadone as
an OAT opioid and 67% of those using buprenor-
phine had severe fatigue symptoms. Four sociodemo-
graphic and clinical factors significantly changed
fatigue levels among methadone users, while two fac-
tors influenced fatigue among those using buprenor-
phine. Methadone is a full opioid agonist associated
with more euphoria and analgesia than the partial
opioid agonist buprenorphine [46]. In a quantitative
study evaluating patients’ experience of using metha-
done and buprenorphine in OAT, unwanted physical
effects, for example, over-sedation, were particularly
pointed out in some methadone cases [47]. These ef-
fects might explain methadone users’ high prevalence
of severe fatigue symptoms and why more sociode-
mographic and clinical factors influenced methadone
users’ the fatigue levels than those using
buprenorphine.
Overall, no single sociodemographic and clinical factor
was associated with substantial changes in fatigue at
baseline or over time in the SUD population. This signi-
fies that fatigue was substantially constant between pa-
tients. However, the mean fatigue level significantly
exceeded the threshold for severe fatigue in the SUD
population, which underlies the importance of identify-
ing patients who simultaneously have several sociodemo-
graphic and clinical risk factors for severe fatigue.
Identifying these patients and treating the underlying
causes of fatigue should be the way to reduce the fatigue
in the population.
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Strengths and limitations
This study has several strengths. We have included 654
patients with SUD that usually are difficult to reach in
health care. Of those, 225 patients were followed up
by two or three annual health assessments, making
longitudinal analyses possible. This study does, how-
ever, have some limitations. First, the patients were
mainly recruited from outpatient clinics receiving
OAT. The majority had opioid dependence, although
this was often combined with other dependencies,
which could affect the generalisability of our results
to other SUD populations. Second, we had a pro-
spective follow-up of only a third of those patients re-
cruited at baseline. This also causes weakness in our
results and makes it necessary to carefully interpret
the longitudinal analyses. Third, due to clinical chal-
lenges, including systematic and patient delays, the
annual health assessments were not precisely con-
ducted one year after the previous health assessment.
This may affect the interpretation of the predicted fa-
tigue level changes from baseline. Fourth, due to data
imputation and inclusion of up to 42 predictors in
the linear mixed model analyses, there is a risk of
Type I error. We dealt with this by presenting the
Bonferroni corrections to all p-values in the analyses.
Conclusion
The present study shows a high symptom burden of fa-
tigue among patients with SUDs, particularly among fe-
males, patients with debt difficulties, and those with
extensive use of benzodiazepines. Identifying severe fa-
tigue and considering fatigue in the follow-ups could
help optimise SUD treatment for these patients. Policy-
makers could take this into consideration when planning
health services.
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Additional file 1. The number of months from baseline to the second
or third health assessment. No.: Number of patients; SD: Standard
deviation; ref.: Reference. The table displays the number of patients with
one, two, and three health assessments, including a nine-item Fatigue Se-
verity Scale score. The table displays the time between baseline and the
second and third health assessments.
Additional file 2. The US-English and the Norwegian versions of FSS-9.
Description: Legends: FSS-9; Nine-item Fatigue Severity Scale. All items in
the FSS-9 are ranged as a Likert scale from 1 to 7, where 1 indicates
“strongly disagree” and 7 “strongly agree”.
Additional file 3. Aspartate aminotransferase to platelet ratio index
(APRI). Description: APRI: Aspartate aminotransferase to platelet ratio
index. The figure displays the APRI score equation. The AST upper limit of
normal range was defined as 45 IU/L (male) and 35 IU/L (female).
Additional file 4. Potential correlations between sociodemographic and
clinical factors and fatigue. The figure shows that potential
sociodemographic and clinical comorbidities may affect fatigue among
patients with substance use disorders.
Additional file 5. Mean (SD) item scores for single items on the FSS-9
at baseline and follow-up. Legend: FSS-9: Nine-item Fatigue Severity
Scale; I: Item; OAT: Opioid agonist therapy; SD: Standard Deviation.
Follow-up: The FSS-9 score on the last health assessment during the
study period among patients with two or more annual health assess-
ments. Mean (SD) item scores for single items on the FSS-9 for patients
using methadone or buprenorphine as OAT opioid.
Additional file 6. Linear mixed model of fatigue (FSS-9) adjusted for
sociodemographic and clinical factors among patients receiving
methadone as an OAT opioid at baseline (N = 209). Legends: APRI:
Aspartate transaminase to platelet ratio index; CI: Confidence interval;
CRP: C-reactive protein; FSS-9: Nine-item Fatigue Severity Scale; eGFR: esti-
mated glomerular filtration rate; HIV: Human Immunodeficiency virus; kPa:
Kilopascal; OAT: Opioid Agonist Therapy. 1) Age per 10 years was centred
according to mean age (43 years) in the study sample at baseline. 2) In-
cludes amphetamine or cocaine use. The OAT opioid ratio: a ratio be-
tween the received dose of OAT opioids per day divided by the
expected mean dose of OAT opioids (buprenorphine 18 mg,
buprenorphine-naloxone 18/4.5 mg or methadone 90 mg). The educa-
tional level: highest level of education was coded 0–4 with 4 as the high-
est educational level. Unstable housing situation: living on the street,
homeless shelter, or with family and friends at any time in the past 30
days prior to the health assessment. Debt difficulties: struggling with re-
paying current illegal and legal debt. Injecting substance use: Having
injected a substance in the past 12 months prior to the health assess-
ment. Frequent use of substances: at least weekly during the past 12
months prior to the health assessment. Viral load of HCV: From − 0.5 to
0.5, where the range ≥ − 0.5 to < 0 represents the low viral load (HCV
PCR < 800,000 IE/ml), and the range from ≤0.5 to > 0 identifies the high
viral load (HCV PCR ≥ 800,000 IE/ml). Zero (0) defined patients without
HCV infection. When using the Bonferroni corrected p-values (αaltered =
0.05 / 43 = 0.0012), the predictors did not affect the FSS-9 sum score sig-
nificantly. The table displays a linear mixed model analysis (Restricted
Maximum Likelihood regression) evaluating sociodemographic and clin-
ical factors’ (predictors) changes in the FSS-9 sum score at baseline and
their influence on changes in the FSS-9 sum score (time trend) per year
from baseline among patients receiving methadone as an OAT opioid.
The predictors’ effect estimates and time trends estimate adjusted mean
differences in the FSS-9 sum score.
Additional file 7. Linear mixed model of fatigue (FSS-9) adjusted for
sociodemographic and clinical factors among patients receiving
buprenorphine as an OAT opioid at baseline (N = 321). Legends: APRI:
Aspartate transaminase to platelet ratio index; CI: Confidence interval;
CRP: C-reactive protein; FSS-9: Nine-item Fatigue Severity Scale; eGFR: esti-
mated glomerular filtration rate; HIV: Human Immunodeficiency virus; kPa:
Kilopascal; OAT: Opioid Agonist Therapy. 1) Age per 10 years was centred
according to mean age (43 years) in the study sample at baseline. 2) In-
cludes amphetamine or cocaine use. The OAT opioid ratio: a ratio be-
tween the received dose of OAT opioids per day divided by the
expected mean dose of OAT opioids (buprenorphine 18 mg,
buprenorphine-naloxone 18/4.5 mg or methadone 90 mg). The educa-
tional level: highest level of education was coded 0–4 with 4 as the high-
est educational level. Unstable housing situation: living on the street,
homeless shelter, or with family and friends at any time during the past
30 days prior to the health assessment. Debt difficulties: struggling with
repaying current illegal and legal debt. Injecting substance use: Having
injected a substance during the past 12 months prior to the health as-
sessment. Frequent use of substances: at least weekly during the past 12
months prior to the health assessment. Viral load of HCV: From − 0.5 to
0.5, where the range ≥ − 0.5 to < 0 represents the low viral load (HCV
PCR < 800,000 IE/ml), and the range ≤ 0.5 to > 0 identifies the high viral
load (HCV PCR ≥ 800,000 IE/ml). Zero (0) defined patients without HCV in-
fection. When using the Bonferroni corrected p-values (αaltered = 0.05 /
43 = 0.0012), the predictors did not affect the FSS-9 sum score signifi-
cantly. The table displays a linear mixed model analysis (Restricted Max-
imum Likelihood regression) evaluating sociodemographic and clinical
factors’ (predictors) changes in the FSS-9 sum score at baseline and their
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influence on changes in the FSS-9 sum score (time trend) per year from
baseline among patients receiving buprenorphine as an OAT opioid. The
predictors’ effect estimates and time trends estimate adjusted mean dif-
ferences in the FSS-9 sum score.
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